Get Help Sign In


IDT DsiRNAs used to map pain pathways in the CNS

Jan 20, 2012

Novel studies carried out at the Université de Sherbrooke discussed in the latest issue of IDT’s DECODED newsletter

CORALVILLE, IA (15th November 2011) – Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, distributes the highly informative newsletter, DECODED. In this quarter’s edition the work carried out by Dr Philippe Sarret and colleagues is discussed in detail. Sarret’s laboratory is based at the Université de Sherbrooke (Quebec, Canada), where researchers are investigating novel ways to develop analgesics and are the first to attempt RNA interference (RNAi) via direct in vivo targeting of genes expressed in the central nervous system (CNS). Using IDT’s Dicer-substrate RNAs (DsiRNAs), the team is specifically targeting pain-modulating pathways such as that mediated by the nueropeptide, neurotensin. DsiRNAs have increased potency compared to traditional small interfering RNAs, achieving sustained knockdown at sub-nanomolar concentrations. Full details of this research can be found by downloading the latest edition of IDT’s DECODED newsletter, which also provides technology overviews, interviews, and procedural recommendations relating to oligonucleotides and their applications.

To find out how IDT can help you with your research, visit or sign up to receive the latest issue of DECODED every quarter via email or post. Alternatively, follow @idtdna on Twitter for all the latest news and updates.


Learn about IDT's role in the fight against COVID-19

Media and PR

For media inquiries please contact IDT Public Relations,